Max allowed unit edit for injectables
Priority Health applies a maximum allowed unit edit per dose, or per day where applicable, to units associated with certain injectable drug HCPCS Level I and II codes.
This applies to all plans: HMO/POS/PPO, Medicare, Priority Health Choice (Healthy Michigan Plan and Medicaid) and individual plans.
Dosage units that exceed Priority Health criteria will be denied for medically unlikely or daily frequency exceeded. Priority Health has reviewed the maximum drug dosage recommended by the FDA or medically accepted indications for these drugs to determine criteria for processing these claims.
If you feel the dosage amount or frequency is medically indicated, you can appeal for the denied unit amount.
- Include the date span: If doses are given over several days, include the date span of when the doses were administered, so as not to exceed the maximum units per dose or day edit.
- Observe minimum frequency: There are also some codes that have minimum frequency limitations (i.e. Prolia given every 6 months, Reclast given yearly), which may be impacted by these edits. Reasonable allowances for early scheduling have been provided.
- Medical records may be requested for review of dosage reported on claim.
- J0129, abatacept (Orencia®)
- J0585, onabotulinum A (Botox)
- J0897, denosumab (Prolia®/Xgeva®)
- J1453, fosaprepitant (Emend®)
- J1745, injection infliximab, 10 mg
- J2469, palonosetron (Aloxi®)
- J1950, Lupron Depot® 3.75mg
- J9217, Lupron Depot® 7.5mg
- J2505, pegfigrastim (Neulasta®)
- J2755, regadenoson (Lexiscan®)
- J7321, hyaluronan or derivative, intra-articular inj, per dose (Hyalgan®/Supartz)
- J7323, hyaluronan or derivative, intra-articular inj, per dose (Euflexxa®)
- J7324, hyaluronan or derivative, intra-articular inj, per dose (Orthovisc®)
- J7325, hyaluronan or derivative, intra-articular inj, 1 mg (Synvisc® or Synvisc® One)
- J7326, hyaluronan or derivative, per dose (Gel-One®)
- J9310, rituximab, 100 mg (Rituxan®)